Annual accounts receivable:
$700.00K-$1.93M(-73.36%)Summary
- As of today (September 19, 2025), CLDX annual accounts receivable is $700.00 thousand, with the most recent change of -$1.93 million (-73.36%) on December 31, 2024.
- During the last 3 years, CLDX annual accounts receivable has risen by +$528.00 thousand (+306.98%).
- CLDX annual accounts receivable is now -77.86% below its all-time high of $3.16 million, reached on December 31, 2018.
Performance
CLDX Accounts receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Quarterly accounts receivable:
$90.00K-$974.00K(-91.54%)Summary
- As of today (September 19, 2025), CLDX quarterly accounts receivable is $90.00 thousand, with the most recent change of -$974.00 thousand (-91.54%) on June 1, 2025.
- Over the past year, CLDX quarterly accounts receivable has dropped by -$1.44 million (-94.13%).
- CLDX quarterly accounts receivable is now -98.40% below its all-time high of $5.61 million, reached on September 30, 2005.
Performance
CLDX Quarterly accounts receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Accounts receivable Formula
Accounts Receivable = Total Credit Sales − Amount Collected from Credit Sales
CLDX Accounts receivable Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
---|---|---|
1 y1 year | -73.4% | -94.1% |
3 y3 years | +307.0% | -7.2% |
5 y5 years | -31.0% | -72.6% |
CLDX Accounts receivable Highs & Lows
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
---|---|---|---|---|---|
3 y | 3-year | -73.4% | +307.0% | -96.6% | at low |
5 y | 5-year | -73.4% | +307.0% | -96.6% | at low |
alltime | all time | -77.9% | >+9999.0% | -98.4% | +1400.0% |
CLDX Accounts receivable History
Date | Annual | Quarterly |
---|---|---|
Jun 2025 | - | $90.00K(-91.5%) |
Mar 2025 | - | $1.06M(+52.0%) |
Dec 2024 | $700.00K(-73.4%) | $700.00K(-17.8%) |
Sep 2024 | - | $852.00K(-44.5%) |
Jun 2024 | - | $1.53M(-42.6%) |
Mar 2024 | - | $2.67M(+1.6%) |
Dec 2023 | $2.63M(+657.3%) | $2.63M(+942.9%) |
Sep 2023 | - | $252.00K(+113.6%) |
Jun 2023 | - | $118.00K(-91.0%) |
Mar 2023 | - | $1.31M(+278.7%) |
Dec 2022 | $347.00K(+101.7%) | $347.00K(+83.6%) |
Sep 2022 | - | $189.00K(+94.8%) |
Jun 2022 | - | $97.00K(-60.1%) |
Mar 2022 | - | $243.00K(+41.3%) |
Dec 2021 | $172.00K(-90.5%) | $172.00K(-12.7%) |
Sep 2021 | - | $197.00K(-60.3%) |
Jun 2021 | - | $496.00K(-72.9%) |
Mar 2021 | - | $1.83M(+1.4%) |
Dec 2020 | $1.80M(+77.5%) | $1.80M(+115.0%) |
Sep 2020 | - | $838.00K(+154.7%) |
Jun 2020 | - | $329.00K(-70.3%) |
Mar 2020 | - | $1.11M(+9.2%) |
Dec 2019 | $1.01M(-67.9%) | $1.01M(+39.6%) |
Sep 2019 | - | $727.00K(-37.9%) |
Jun 2019 | - | $1.17M(-49.3%) |
Mar 2019 | - | $2.31M(-27.0%) |
Dec 2018 | $3.16M(+68.2%) | $3.16M(-0.4%) |
Sep 2018 | - | $3.17M(-7.2%) |
Jun 2018 | - | $3.42M(-14.9%) |
Mar 2018 | - | $4.02M(+113.8%) |
Dec 2017 | $1.88M(+5.4%) | $1.88M(-37.6%) |
Sep 2017 | - | $3.01M(+121.7%) |
Jun 2017 | - | $1.36M(-1.8%) |
Mar 2017 | - | $1.38M(-22.4%) |
Dec 2016 | $1.78M(+83.9%) | $1.78M(+13.0%) |
Sep 2016 | - | $1.58M(+41.5%) |
Jun 2016 | - | $1.12M(+31.8%) |
Mar 2016 | - | $847.00K(-12.7%) |
Dec 2015 | $970.00K(+127.2%) | $970.00K(+84.1%) |
Sep 2015 | - | $527.00K(+21.4%) |
Jun 2015 | - | $434.00K(-36.1%) |
Mar 2015 | - | $679.00K(+59.0%) |
Dec 2014 | $427.00K | $427.00K(-85.3%) |
Sep 2014 | - | $2.90M(+453.3%) |
Date | Annual | Quarterly |
---|---|---|
Jun 2014 | - | $525.00K(+72.1%) |
Mar 2014 | - | $305.00K(-37.6%) |
Dec 2013 | $489.00K(+1011.4%) | $489.00K(-45.1%) |
Sep 2013 | - | $890.00K(+7316.7%) |
Jun 2013 | - | $12.00K(-88.5%) |
Mar 2013 | - | $104.00K(+136.4%) |
Dec 2012 | $44.00K(-74.1%) | $44.00K(+37.5%) |
Sep 2012 | - | $32.00K(-47.5%) |
Jun 2012 | - | $61.00K(-56.4%) |
Mar 2012 | - | $140.00K(-17.6%) |
Dec 2011 | $170.00K(-47.5%) | $170.00K(-16.7%) |
Sep 2011 | - | $204.00K(+25.2%) |
Jun 2011 | - | $163.00K(-32.9%) |
Mar 2011 | - | $243.00K(-25.0%) |
Dec 2010 | $324.00K(-40.4%) | $324.00K(+5300.0%) |
Dec 2009 | $544.00K(-67.8%) | - |
Dec 2008 | $1.69M(>+9900.0%) | - |
Dec 2007 | $6000.00(-96.7%) | $6000.00(-98.3%) |
Dec 2006 | $183.80K(-52.1%) | - |
Sep 2006 | - | $350.50K(-25.1%) |
Jun 2006 | - | $468.20K(-10.0%) |
Mar 2006 | - | $520.00K(+35.6%) |
Dec 2005 | $383.40K(-82.6%) | $383.40K(-93.2%) |
Sep 2005 | - | $5.61M(+3.1%) |
Jun 2005 | - | $5.45M(+512.8%) |
Mar 2005 | - | $888.90K(-59.7%) |
Dec 2004 | $2.21M(+49.7%) | $2.21M(+707.5%) |
Sep 2004 | - | $273.10K(-49.4%) |
Jun 2004 | - | $540.10K(-67.3%) |
Mar 2004 | - | $1.65M(+12.2%) |
Dec 2003 | $1.47M(+537.9%) | $1.47M(+159.1%) |
Sep 2003 | - | $568.50K(-3.0%) |
Jun 2003 | - | $585.80K(-7.7%) |
Mar 2003 | - | $634.50K(+174.8%) |
Dec 2002 | $230.90K(-13.6%) | $230.90K(-89.1%) |
Sep 2002 | - | $2.12M(+847.9%) |
Jun 2002 | - | $224.10K(-1.5%) |
Mar 2002 | - | $227.50K(-14.9%) |
Dec 2001 | $267.20K(+74.1%) | $267.20K(+65.4%) |
Sep 2001 | - | $161.50K(-57.9%) |
Jun 2001 | - | $383.50K(+119.1%) |
Mar 2001 | - | $175.00K(+14.0%) |
Dec 2000 | $153.50K(-64.4%) | $153.50K(-64.4%) |
Dec 1999 | $431.70K | $431.70K |
FAQ
- What is Celldex Therapeutics, Inc. annual accounts receivable?
- What is the all time high annual accounts receivable for Celldex Therapeutics, Inc.?
- What is Celldex Therapeutics, Inc. annual accounts receivable year-on-year change?
- What is Celldex Therapeutics, Inc. quarterly accounts receivable?
- What is the all time high quarterly accounts receivable for Celldex Therapeutics, Inc.?
- What is Celldex Therapeutics, Inc. quarterly accounts receivable year-on-year change?
What is Celldex Therapeutics, Inc. annual accounts receivable?
The current annual accounts receivable of CLDX is $700.00K
What is the all time high annual accounts receivable for Celldex Therapeutics, Inc.?
Celldex Therapeutics, Inc. all-time high annual accounts receivable is $3.16M
What is Celldex Therapeutics, Inc. annual accounts receivable year-on-year change?
Over the past year, CLDX annual accounts receivable has changed by -$1.93M (-73.36%)
What is Celldex Therapeutics, Inc. quarterly accounts receivable?
The current quarterly accounts receivable of CLDX is $90.00K
What is the all time high quarterly accounts receivable for Celldex Therapeutics, Inc.?
Celldex Therapeutics, Inc. all-time high quarterly accounts receivable is $5.61M
What is Celldex Therapeutics, Inc. quarterly accounts receivable year-on-year change?
Over the past year, CLDX quarterly accounts receivable has changed by -$1.44M (-94.13%)